Autres langues Syndax Pharmaceuticals, Inc.

Actions

SNDX

US87164F1057

Temps réel estimé Cboe BZX Autres places de cotation 16:10:30 06/06/2024			Varia. 5j.	Varia. 1 janv.
19,28 ^USD	+0,34 %		-1,89 %	-12,42 %

13:00	Syndax Pharmaceuticals annonce son intention de passer à la phase 1b de l'essai évaluant Revumenib dans le traitement du MSS CRC métastatique récidivant ou réfractaire	CI
16/05	Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC	13:00
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference	05/06
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/06
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors	15/05
Syndax Pharmaceuticals, Inc. Announces Board Changes	15/05
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference	09/05
Syndax Pharmaceuticals Q1 Net Loss Widens	08/05
Syndax Pharmaceuticals : First Quarter 2024 Conference Call	08/05
Syndax: Q1 Earnings Snapshot	08/05
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/05
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	01/05
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27/03
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26/03
Syndax Says Revumenib NDA Granted FDA Priority Review	26/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Syndax Pharmaceuticals, Inc.

Actions

SNDX

US87164F1057

Autres langues

Filtres